Display options
Cite
Yavuz GO, Yılgör A, Yavuz IH, et al. Effects of omalizumab therapy on peripheral nerve functions: short observational study. Postepy Dermatol Alergol. 2018;36(2):211-216doi: 10.5114/ada.2018.74834.
Yavuz, G. O., Yılgör, A., Yavuz, I. H., Milanlıoğlu, A., Çilingir, V., Çağaç, A., Ozturk, M., & Bilgili, S. G. (2019). Effects of omalizumab therapy on peripheral nerve functions: short observational study. Postepy dermatologii i alergologii, 36(2), 211-216. https://doi.org/10.5114/ada.2018.74834
Yavuz, Goknur Ozaydın, et al. "Effects of omalizumab therapy on peripheral nerve functions: short observational study." Postepy dermatologii i alergologii vol. 36,2 (2019): 211-216. doi: https://doi.org/10.5114/ada.2018.74834
Yavuz GO, Yılgör A, Yavuz IH, Milanlıoğlu A, Çilingir V, Çağaç A, Ozturk M, Bilgili SG. Effects of omalizumab therapy on peripheral nerve functions: short observational study. Postepy Dermatol Alergol. 2019 Apr;36(2):211-216. doi: 10.5114/ada.2018.74834. Epub 2018 Apr 03. PMID: 31320856; PMCID: PMC6627259.
Copy Download .nbib Format: NLM
Share it on

Postepy Dermatol Alergol. 2019 Apr;36(2):211-216. doi: 10.5114/ada.2018.74834. Epub 2018 Apr 03.

Effects of omalizumab therapy on peripheral nerve functions: short observational study.

Postepy dermatologii i alergologii

Goknur Ozaydın Yavuz, Abdullah Yılgör, Ibrahim Halil Yavuz, Aysel Milanlıoğlu, Vedat Çilingir, Aydın Çağaç, Murat Ozturk, Serap Gunes Bilgili

Affiliations

  1. Department of Dermatology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.
  2. Department of Neurology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey.

PMID: 31320856 PMCID: PMC6627259 DOI: 10.5114/ada.2018.74834

Abstract

INTRODUCTION: Peripheral neuropathy (PN) is a common neurological condition causing symmetrical and diffuse damage in nerves. The etiology of PN includes systemic diseases, toxic exposure, medications, infections, and hereditary diseases. Omalizumab is a humanized monoclonal anti-IgE antibody that exerts its activity by binding to free IgE in circulation.

AIM: To investigate the relationship between omalizumab and peripheral neuropathy.

MATERIAL AND METHODS: The study included 30 patients who underwent omalizumab therapy (Xolair) due to the diagnosis of chronic urticaria. A detailed neurological and physical examination was performed in each patient both before and 3 months after the therapy. Electrophysiological examination was also performed using a Medelec Synergy instrument.

RESULTS: The 30 patients included 8 (26.7%) men and 22 (73.3%) women with a mean age of 37.5 ±14.14 years. No serious side effect of the medication was detected in any patient although local wound irritation occurred in 3 (10%) patients. Moreover, no change occurred in the pre-treatment Neuropathy Symptom Score (NSS) or Neurological Disability Score (NDS) of the patients and no pathological values that could result in neuropathy were observed during motor/sensory nerve conduction. However, significant changes were detected in the sensory and motor components of the nerves with regards to pre- and post-treatment values.

CONCLUSIONS: Omalizumab therapy caused no peripheral neuropathy in any of our patients but altered the latency, amplitude, and velocity values of the peripheral nerves.

Keywords: chronic urticaria; neuropathy; omalizumab

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Nature. 1999 Nov 25;402(6760 Suppl):B18-23 - PubMed
  2. Neurochem Res. 1992 Sep;17(9):939-51 - PubMed
  3. Clin Rev Allergy Immunol. 2005 Aug;29(1):31-48 - PubMed
  4. Clin Exp Allergy. 2007 Feb;37(2):197-207 - PubMed
  5. Clin Exp Allergy. 2009 Jun;39(6):788-97 - PubMed
  6. Ann Allergy Asthma Immunol. 2009 Nov;103(5):442-5 - PubMed
  7. Am Fam Physician. 2010 Apr 1;81(7):887-92 - PubMed
  8. Allergy Asthma Clin Immunol. 2005 Jun 15;1(2):65-80 - PubMed
  9. Ann Allergy Asthma Immunol. 2010 Dec;105(6):493-5 - PubMed
  10. Clin Rheumatol. 2013 Sep;32(9):1407-12 - PubMed
  11. Int J Clin Pharm. 2015 Feb;37(1):36-43 - PubMed
  12. Clin Drug Investig. 2015 Mar;35(3):159-68 - PubMed
  13. Mayo Clin Proc. 2015 Jul;90(7):940-51 - PubMed
  14. Arthritis Rheumatol. 2016 Sep;68(9):2274-82 - PubMed
  15. Eur J Dermatol. 2016 Aug 1;26(4):404-5 - PubMed
  16. ACG Case Rep J. 2016 Apr 15;3(3):187-9 - PubMed
  17. J Allergy Clin Immunol. 2017 May;139(5):1489-1495.e5 - PubMed
  18. Br J Clin Pharmacol. 2017 Oct;83(10):2330-2332 - PubMed
  19. J Allergy Clin Immunol. 2018 Feb;141(2):638-649 - PubMed
  20. Muscle Nerve. 1988 Jul;11(7):661-7 - PubMed
  21. Allergy Asthma Immunol Res. 2018 Jan;10(1):83-87 - PubMed
  22. Allergy Asthma Immunol Res. 2018 Mar;10(2):121-130 - PubMed

Publication Types